Matinas BioPharma (NYSEAMERICAN:MTNB) has been given a $6.00 target price by research analysts at Maxim Group in a note issued to investors on Monday. The firm currently has a “buy” rating on the stock. Maxim Group’s target price suggests a potential upside of 450.46% from the company’s current price.
Matinas BioPharma stock traded up $0.04 on Monday, hitting $1.09. The stock had a trading volume of 533,292 shares, compared to its average volume of 175,809. Matinas BioPharma has a 52 week low of $0.83 and a 52 week high of $3.39. The firm has a market capitalization of $96.67, a PE ratio of -2.95 and a beta of 0.39.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC lifted its holdings in Matinas BioPharma by 126.0% during the 4th quarter. Virtu Financial LLC now owns 106,146 shares of the company’s stock worth $123,000 after purchasing an additional 59,188 shares during the last quarter. American Century Companies Inc. acquired a new stake in Matinas BioPharma during the 4th quarter worth approximately $155,000. Deutsche Bank AG lifted its holdings in Matinas BioPharma by 184.8% during the 4th quarter. Deutsche Bank AG now owns 148,042 shares of the company’s stock worth $171,000 after purchasing an additional 96,054 shares during the last quarter. Yellowstone Partners LLC acquired a new stake in Matinas BioPharma during the 3rd quarter worth approximately $190,000. Finally, BlackRock Inc. lifted its holdings in Matinas BioPharma by 3.4% during the 4th quarter. BlackRock Inc. now owns 2,530,508 shares of the company’s stock worth $2,935,000 after purchasing an additional 84,226 shares during the last quarter.
Matinas BioPharma Company Profile
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.